| Literature DB >> 26660881 |
Yaolin Xu1, Dana C Baiu2, Jennifer A Sherwood1, Meghan R McElreath2, Ying Qin3, Kimberly H Lackey4, Mario Otto2, Yuping Bao1.
Abstract
Specific targeting is a key step to realize the full potential of iron oxide nanoparticles in biomedical applications, especially tumor-associated diagnosis and therapy. Here, we developed anti-GD2 antibody conjugated iron oxide nanoparticles for highly efficient neuroblastoma cell targeting. The antibody conjugation was achieved through an easy, linker-free method based on catechol reactions. The targeting efficiency and specificity of the antibody-conjugated nanoparticles to GD2-positive neuroblastoma cells were confirmed by flow cytometry, fluorescence microscopy, Prussian blue staining and transmission electron microscopy. These detailed studies indicated that the receptor-recognition capability of the antibody was fully retained after conjugation and the conjugated nanoparticles quickly attached to GD2-positive cells within four hours. Interestingly, longer treatment (12 h) led the cell membrane-bound nanoparticles to be internalized into cytosol, either by directly penetrating the cell membrane or escaping from the endosomes. Last but importantly, the uniquely designed functional surfaces of the nanoparticles allow easy conjugation of other bioactive molecules.Entities:
Year: 2014 PMID: 26660881 PMCID: PMC4675334 DOI: 10.1039/C4TB00840E
Source DB: PubMed Journal: J Mater Chem B ISSN: 2050-750X Impact factor: 6.331